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Key Points
• Anergic features of B cells
of MC rapidly reverse after
eradication of HCV with
DAAs.
• Phenotypic and functional
features of virus-specific
B-cell exhaustion persist for
several months after HCV
eradication.
Hepatitis C virus (HCV) causesmixed cryoglobulinemia (MC) by driving clonal expansion
of IgM1CD271 B cells. These cells display both the features of anergy induced by
continual engagement of the B-cell receptor (BCR), such as high expression of
phosphorylated extracellular signal–regulated kinase (pERK) and reduced lifespan,
and of virus-specific exhaustion, such as CD21low phenotype and a defective response
to ligationofBCRandToll-like receptor 9 (TLR9).MCusually regresses after eradication
of HCV with interferon, whose immunomodulatory activity might contribute to this
effect. We investigated the phenotypic and functional changes in clonal B cells of MC
patients with sustained virologic responses to direct-acting antivirals (DAAs), which
lack immunomodulatory properties. We found that high pERK expression and
accelerated apoptosis revert within 4 weeks after beginning therapy, whereas clonal
B cells unresponsive to TLR9 stimulation persist for at least 24 weeks, although they
may partially rescue normal CD21 expression. Thus, similar to mousemodels, features
of anergy in MC B cells rapidly revert after disengagement from HCV, whereas virus-specific exhaustion imparts a durable
inhibitory imprint on cell function. Treatment of HCV1 MC with DAAs provides a valuable tool for untangling the molecular
mechanisms of anergy and exhaustion in human B cells. (Blood. 2017;130(1):35-38)
Introduction
Mixed cryoglobulinemia (MC) is a lymphoproliferative disorder
caused by hepatitis C virus (HCV) and is characterized by clonal
expansion of CD271IgM1B cells producing a rheumatoid factor often
encoded by theVH1-69 andVk3-20 genes.
1,2 It is widely believed3 that
the clonal expansion ofVH1-69
1Bcells inMCand inHCV-associated
non-Hodgkin lymphomas (NHLs) is triggered by the protracted
stimulation by an HCV antigen that, however, remains elusive.4
Clonal B cells of patients with HCV1 MC display peculiar
phenotypic and functional features. In fact, they commonly express low
levels of CD21 (CD21low B cells), express an array of inhibitory and
apoptosis-related genes and a distinctive pattern of homing receptors
(including CD11c1), fail to flux calcium upon B-cell receptor (BCR)
triggering and proliferate in response to the stimulation of BCR or
of Toll-like receptor 9 (TLR9), and are prone to die by apoptosis.5-7
Identical CD21low B cells are expanded in patients with common
variable immunodeficiency (CVID)8 and in HIV-infected individuals.9
These CD21low B cells have been defined “exhausted”9 for their
similarity with virus-specific exhausted T cells.10 For some of their
characteristics, human CD21low B cells recall the murine “aged
B cells” (ABCs) increased in aged mice,11,12 which are
CD21lowCD11c1 B cells expressing the T-box expressed in T cells
(T-bet) transcriptional factor and are important for the control of
viral infections.13 However, ABCs lack many signatures of human
CD21low exhausted B cells, such as the fact that they robustly
respond to the stimulation of TLR7 or TLR9.11-13
CD21low B cells of HCV1 MC7 and CVID patients8 display high
constitutive expression of the active phosphorylated form of extracellular
signal–regulated kinase (pERK); this signature, together with reduced
calcium flux and proneness to apoptosis, makes them closely resemble
murineBcellsmadeanergicbycontinualBCRengagementbyantigen.14 In
murine anergicBcells, constitutiveERKsignaling and reduced lifespan are
reversedbydissociationofselfantigenfromBCRusinghaptencompetition,
indicating the need for continualBCRoccupancy formaintaining anergy.15
Here, we exploited the newly available direct-acting antivirals (DAAs),
which rapidly suppressHCVviremia inHCV1MCpatients16 and lack the
immunomodulatory properties of interferon, to untangle the effects of BCR
disengagement in a human model of virus-driven anergy and exhaustion.
Study design
Twenty-four patientswithHCV1MCwere treatedwith guideline-tailoredDAA
therapy as described previously16; all patients had negative HCV viremia at the
end of treatment and sustained virologic responses (SVRs) through a follow-up
of 12 (SVR12) to 24 (SVR24)weeks after the end of treatment. All patientswere
investigated for phenotypic changes in clonal B-cell populations after the cure of
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Figure 1. Phenotypic and functional changes in clonal B cells of HCV1 MC patients after clearance of HCV infection by DAA therapy. (A) Constitutive pERK
expression by whole B cells, expressed as mean fluorescence intensity (MFI), is higher in untreated MC patients than in healthy donors (HD), whereas (B) the relative
increase of pERK induced by BCR ligation with anti-immunoglobuliln, expressed as fold increase compared with constitutive pERK MFI, is reduced in MC B cells. Bars denote
the means. (C) MC B cells are more prone to spontaneous apoptosis than HD B cells. (D) pERK constitutive expression in MC B cells decreases significantly 4 weeks after
beginning DAA compared with pretherapy (pre-th), whereas (E) the BCR-induced fold-increase of pERK remains unmodified at this time point. (F) Spontaneous apoptosis is
significantly reduced in MC B cells 4 weeks after beginning DAA therapy and at the end of treatment (EOT). (G) Changes in the proportions of CD21low B cells among
circulating B cells in a cohort of 24 MC patients treated with DAA. (H) Changes in the proportions of VH1-69
1 B cells in 5 MC patients treated with DAA. (I) In one MC patient,
VH1-69
1 B cell expansion persists unmodified after DAA therapy, but a large proportion of clonal B cells rescue a CD21high phenotype at SVR24. (J) MC VH1-69
1 B cells
remain unable to proliferate efficiently in response to TLR9 ligation at SVR24. (Ji) Electronic gating of VH1-69
2 and VH1-69
1 B cells; the CD20dim cells are plasmablasts.
(Jii-Jiii) Analysis of the proliferative responses of (ii) VH1-69
2 and (iii) VH1-69
1 B cells. Percentages denote the number of cells that started dividing (precursor cohort);
numbers denote cell divisions as calculated by the FlowJo software. CFSE, carboxyfluorescein diacetate succinimidyl ester.
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infection; 10 patients also underwent functional studies of ERK signaling,
apoptosis, and proliferative responses to stimuli. Patients, B-cell phenotyping,
and functional assays are described in detail in supplemental Methods, available
on the BloodWeb site. This study was approved by the local institutional ethics
committee, and informed consent was obtained from all patients.
Results and discussion
ClonalBcells ofmost patientswith untreatedHCV1MChadhighbasal
levels of pERK (Figure 1A), while the relative increment (fold increase)
of pERK upon BCR stimulation was reduced (Figure 1B); uncoupling
of constitutive and BCR-induced ERK activation was previously
observed in CD21low B cells of HCV1 MC7 and CVID8 patients.
Furthermore, patients’B cells showed increased apoptosis upon in vitro
culture without stimuli (Figure 1C). In addition to these anergy-like
features,14,15 clonal B cells displayed the features of exhausted B cells,5-7
as theyweremostlyCD21lowIgM1CD271CD11c1FCRL41 and failed
to proliferate in response to BCR or TLR9 stimulation (not shown).
Four weeks after the beginning of DAA therapy, constitutive ERK
phosphorylation was significantly reduced compared with pretherapy
levels (Figure 1D), although BCR-induced ERK phosphorylation
increased only slightly (Figure 1E).At this time point, spontaneous in vitro
apoptosis was also significantly reduced (Figure 1F). The possibility that
early normalization of constitutive ERK activation and apoptosis was due
toreplacementofclonalBcellsbynormalBcellscontrastswith the fact that
the proportions of CD21low B cells in these patients were unchanged at
week 4 of therapy (54.9% 6 25% vs 53.8% 6 23% pretherapy).
Our results support the idea that, as in the case of antigen-induced
reversibleB-cell anergy inmice,15 reduction in the lifespan ofB cells of
HCV1 MC patients depended on chronic stimulation and could be
reversed by disengagement of the BCR. Although it is believed that
reduced lifespan ofmurine anergic B cells is largely due to unfavorable
competition forB-cell–activating factor,17 the rapid increase of lifespan
after BCR disengagement suggests that chronic BCR signaling is
sufficient to initiate apoptosis.15Thus,we investigatedwhether reduced
lifespanofMCBcellswas related toERKsignaling; treatingMCBcells
with theMEK/ERK inhibitor U0126, as previously described,8 failed to
reduce spontaneous in vitro apoptosis (not shown), suggesting that ERK
signaling is not directly involved in their proapoptotic pathway.
The proportions of CD21low B cells declined steadily up to SVR24
(Figure 1G), although they remained on average higher than in healthy
donors (mean6SD, 5.8%62.5%).However, the proportions ofVH1-
69-expressingBcells remained stableup toSVR24 in3out of 5patients
(Figure 1H), suggesting that phenotypic changes occurred in clonal
B cells after eradication of HCV, as previously observed inHCV1MC
patients treated with interferon.18 Indeed, in these 5 patients, the pro-
portions of VH1-69
1CD21low cells decreased from 84.8% 6 11.1%
pretherapy to 36.4% 6 11.8% at SVR24 (P 5 .043) (supplemental
Results), indicating a reversion of the CD21low phenotype. Figure 1I
shows representative cytograms from 1 patient. Despite phenotypic
changes, long-lived clonal B cells failed to restore their capacity
to proliferate in response to TLR9 stimulation. Indeed, the number
of VH1-69
1 cells entering division (precursor cohort) in 3 patients
(supplemental Results) was 2.8 6 1.2 pretherapy and 5.3 6 2.4 at
SVR24, whereas it was 35.6 6 6.5 and 32.6 6 8.5, respectively, in
autologous VH1-69
2 cells. Figure 1J shows representative cytograms
from 1 patient. This indicates that HCV-driven B-cell exhaustion
makes use of durable reprogramming mechanisms irrespective of
the CD21low phenotype, as suggested by previous studies.18,19
Recently,T-bet1CD21lowCD11c1Bcells, similar tomurineABCs,
were found increased in patients with chronic hepatitis C or cirrhosis
without MC, and, importantly, eradication of HCV with DAAs led to
their decrease, indicating dependence on infection.20 Although we did
not investigate and cannot exclude T-bet expression in clonal B cells of
MC patients, their CD271IgD1IgM1 B cells1,2 are phenotypically
distinct from the T-bet1 B cells of HCV-infected patients without
MC, which are mostly CD272IgD2IgM2IgG1 class-switched cells.20
Interestingly in this regard, while the T-bet1CD272IgG1 B cells
of HCV-infected patients decrease after antiviral therapy, the few
T-bet1IgD1IgM1 B cells appear to increase.20
In summary, we show that clonal B cells of HCV1 MC display
signatures of anergy induced by continual BCR occupancy and of
exhaustion driven by chronic viral infection. Anergy features (pERK
overexpression and accelerated apoptosis) rapidly revert after disen-
gagement from HCV, while phenotypic and functional features of
exhaustion persist for several months. The rapid clearance of HCV
viremia with DAAs, which unlike interferon do not act as immunolog-
ical modulators, offers a unique model for untangling the interplay of
virus-driven anergy and exhaustion in human B cells.
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Persistence of exhaustion in cured hep C
-----------------------------------------------------------------------------------------------------
David E. Kaplan UNIVERSITY OF PENNSYLVANIA; CORPORAL MICHAEL J. CRESCENZ VA MEDICAL CENTER
In this issue of Blood, Del Padre et al1 evaluated the impact of eliminating chronic
antigen exposure on B-cell exhaustion in the human therapeutic setting of direct-
acting antiviral therapy for chronic hepatitis C virus infection (HCV) complicated
by mixed cryoglobulinemia (MC). The phenotype of hepatitis C–related MC
B cells has been previously demonstrated by this group and others2 to include
low-level CD21 expression (CD21low) and hypoproliferation in response to
stimulation either through the B-cell receptor or Toll-like receptor 9, imperfectly
termed “exhausted” or “anergic.” At baseline, CD21low B cells from HCV-
infected patients expressed markers of chronic activation, with elevated and near-
maximal basal levels of phosphorylated extracellular signal–regulated kinase, and
were also predisposed to apoptosis. During oral direct-acting antiviral therapy, the
authors observed that by 4 weeks (at which point, most patients have no
circulating HCV RNA), these basal abnormalities at least partially normalized.
During longitudinal follow-up after patients were documented as cured, the
overall frequency of CD21low cells progressively declined from 50% to 30% of
circulating B cells. However, the frequency of VH1-691 B cells specific for HCV-
related MC generally remained stable, although some regained CD21 expression.
Despite partial resolution of the exhaustion phenotype, surviving VH1-691 B cells
remained hypoproliferative upon Toll-like receptor 9 ligation, suggesting that the
B-cell exhaustion phenotype is durably programmed into antigen-specific B cells
during long-term extracellular antigen exposure.
M ixed cryoglobulinemia is one of severalB-cell proliferative disorders that may
result from chronic hepatitis C infection, and it
is thought to be driven by expansion of HCV
envelope-specific B cells that preferentially use
immunoglobulin gene segments VH1-69 and
Vk3-20,3 and to evolve rheumatoid factor
activity through somatic hypermutation.4
Although MC is an infrequent complication of
chronic hepatitis C infection, the technological
ability to identify and isolate HCV-specific
B cells via an anti-idiotype VH1-69–specific
antibody (G6) has made this condition an
important model for studying humoral
immune dysfunction during human chronic
viral infection. Prior studies have identified
that VH1-691 B cells manifest genetic
signatures of enhanced interferon-mediated
responsiveness, apoptosis, and B-cell
anergy; are phenotypically most commonly
CD271/IgM1/CD11c1/CD21low; are prone
to apoptosis; and are hyporesponsive to B-cell
receptor crosslinking.2,5
B-cell anergy, an adaptive response to
chronic antigen exposure for autoreactive
B cells, has been postulated to be a
vulnerability exploited by pathogens to
evade humoral sterilization and enhance
permissiveness for chronic bloodborne
infections. Recent data suggest that the
T-box expressed in T cells (T-bet)
transcription factor, critical for inducing
sterilizing humoral immunity in acute
infections,6 may also regulate the exhausted
state in both autoreactive7 and antigen-
induced anergic B cells.8,9 No data to date
specifically link the anergy properties
observed in cryoglobulin-producing B cells
and T-bet, but there are phenotypic
similarities (CD11c1/CD21low) that suggest
a possible relationship that should be
explored; rapid upregulation of T-bet in
convalescent CD21low B cells upon
reexposure to autologousHCV strains ex vivo
has been observed,8 suggesting a link between
B-cell receptor ligation, T-bet, and the
CD21low exhaustion phenotype.
How are these data clinically relevant?
The persistence of VH1-69 B cells after
sustained virological response clearly
explains the persistence of symptomatic
cryoglobulinemic vasculitis observed in some
HCV-cured patients.10 However, these data
may have broader implications on the early and
late immunopathogenesis of chronic infection.
That antigen-specific B-cell anergy is durably
programmed suggests that B-cell exhaustion
might rapidly redevelop in the setting of
reinfection, potentially contributing to the lack
of protective immunity observed in many
resolved chronic infections. The current study
creates the context for further exploration of the
mechanisms associated with induction of B-cell
exhaustion in vivo. Once the regulation of B-cell
anergy in chronic infection is better understood,
therapeutic manipulation could significantly
affect the outcomes not only of chronic hepatitis
C, but also of other chronic viral and parasitic
infections.
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